Tesamorelin Testing
MW: 5135.89 g/molHalf-life: ~26 minutesStatus: FDA-approved
N-terminally modified 44-aa GHRH analog, FDA-approved as Egrifta.
Mechanism of action
GHRH(1-44) with a trans-3-hexenoyl N-terminal modification that confers protease resistance. Studied primarily for HIV-associated lipodystrophy, where it reduces visceral adipose tissue.
Research areas
- ●HIV-associated lipodystrophy (FDA-approved as Egrifta)
- ●NAFLD/NASH (Phase 3 EFRUXIFERMIN trial comparators)
- ●Cognitive aging (NIH-funded studies)
What we test on Tesamorelin
Intact mass to confirm hexenoyl modification; RP-HPLC purity with extended hydrophobic gradient; SEC for aggregation.
Standard GH Secretagogues Panel
- ✓RP-HPLC purity
- ✓ESI-MS identity
- ✓Amino acid analysis
- ✓Residual solvents (GC-MS)
Common impurities & failure modes
- Missing N-terminal modification
−98 Da; the resulting molecule is effectively sermorelin extended by 15 residues, with much shorter half-life.
- Truncation
Long peptide; C-terminal QQGESNQERGARARL stretch is particularly prone to deletions.
- Aggregates
Hydrophobic N-terminal lipid drives self-association; SEC required.
Regulatory status
FDA-approved (Egrifta 2010; Egrifta SV 2019).
Related GH Secretagogues peptides
CJC-1295 (DAC)
3647.28 g/mol
GHRH analog with Drug Affinity Complex for extended half-life (~8 days).
CJC-1295 (no DAC) / Modified GRF 1-29
3367.93 g/mol
GHRH analog without DAC, shorter half-life than CJC-1295 with DAC.
GHRP-2
817.97 g/mol
Synthetic hexapeptide stimulator of GH release.
GHRP-6
872.97 g/mol
Hexapeptide stimulating GH secretion via the ghrelin receptor.
Hexarelin
887.04 g/mol
Potent hexapeptide GH secretagogue; also studied for cardiac effects.
Ibutamoren (MK-677)
528.66 g/mol
Orally active non-peptide GH secretagogue / ghrelin agonist.